Covid-19: Do many people have pre-existing immunity?

Doshi, Peter

doi:10.1136/bmj.m3563

Cited by 93 publications

(98 citation statements)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We hypothesize that prior exposure to HCoV OC43 virus facilitates T-cell based immune responses to SARS CoV-2. While previous work supports this hypothesis [3,4,5,15], further research is needed to gain deeper insights into the underlying immunological processes. According to a recent simulation study [16], crossimmunity between HCoV OC43 and SARS-CoV-2 could affect transmission dynamics of SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 90%

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Dugas

Grote-Westrick

Merle

et al. 2020

Preprint

View full text Add to dashboard Cite

Most COVID-19 patients experience a mild disease; a minority suffers from critical disease.We report about a biomarker validation study regarding 296 patients with confirmed SARS-CoV-2 infections from four tertiary care referral centers in Germany and France.Patients with critical disease had significantly less anti-HCoV OC43 nucleocapsid protein antibodies compared to other COVID-19 patients (p=0.007). In multivariate analysis, OC43 negative inpatients had an increased risk of critical disease, higher than the risk by increased age or BMI, and lower than the risk by male sex. A risk stratification based on sex and OC43 serostatus was derived from this analysis.Our results indicate that prior infections with seasonal human coronaviruses can protect against a severe course of COVID-19. Anti-OC43 antibodies should be measured for COVID-19 inpatients and considered as part of the risk assessment. We expect individuals tested negative for anti-OC43 antibodies to particularly benefit from vaccination, especially with other risk factors prevailing.

show abstract

Section: Discussionmentioning

confidence: 90%

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Dugas

Grote-Westrick

Merle

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, multiple studies have identified pre-existing cellular immunity that may be effective against SARS-CoV-2 in 20%-50% of participant samples. [55][56][57] If so, the proportion of people who need to be infected to reach herd immunity may be much lower than originally estimated. Thresholds for herd immunity remain a contested, but crucial issue as they determine the projected potential total fatalities.…”

Section: Pandemic Spreadmentioning

confidence: 96%

Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic

Ioannidis

2020

Eur J Clin Investigation

157

162

View full text Add to dashboard Cite

Almost a year since the first known cases in November 2019 in Wuhan, COVID-19 has been linked to over 1 million deaths and active epidemic waves continue to spread. It is important to overview the emerging epidemiological footprint and understand the current situation and its implications for the future of the pandemic. It is unknown exactly how long a full cycle for the pandemic spreading worldwide may take, and this is likely to vary across different locations. Regardless,

show abstract

“…The covid-19 vaccine protocols should be scrutinised by the widest possible readership, to open a critical discussion of many questions about their design and conduct. These include why children, immunocompromised people, and pregnant women have been excluded from most trials; whether the right primary endpoint has been chosen; whether safety is being adequately evaluated; and whether gaps in our understanding of the clinical implications of pre-existing T cell responses to SARS-CoV-2 are being addressed 11…”

Section: Eyes On Deckmentioning

confidence: 99%

Covid-19 vaccine trial protocols released

Doshi¹

2020

BMJ

Self Cite

View full text Add to dashboard Cite

The ongoing phase III trials for covid-19 vaccines are some of the most consequential randomised trials ever done. In September, following months of campaigning for greater openness, 1 2 four manufacturers made their full study protocols publicly available. 3-6 The publications create a rare opportunity for "real time transparency" in which the conduct of clinical trials is opened to public scrutiny while the studies are still under way.

show abstract

Covid-19: Do many people have pre-existing immunity?

Abstract: It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responses

Cited by 93 publications

References 26 publications

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic

Covid-19 vaccine trial protocols released

Contact Info

Product

Resources

About